The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Visual abstract | Phase III trial of Iomab-B versus conventional conditioning pre-HSCT in patients with R/R AML (SIERRA)
The AML Hub is pleased to present a visual abstract summarizing key results from the randomized phase III SIERRA trial comparing Iomab-B prior to hematopoietic stem cell transplant (HSCT) with conventional care in patients with relapsed or refractory acute myeloid leukemia.1
These data were presented by Giralt1 at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, where Giralt highlighted the key safety and efficacy findings from this pivotal trial of Iomab-B, a first-in-class anti-CD45-conjugated radiotherapy. Older patients with relapsed/refractory acute myeloid leukemia have a poor prognosis, with high rates of failure often preventing access to HSCT. Improving conditioning regimens may therefore result in better HSCT outcomes for these patients.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content